EUCTR2005-000712-27-PTActive, not recruitingNot Applicable
An open-label trial with TMC125 in HIV-1 infected subjects, who were randomized to a TMC125 treatment arm in a sponsor-selected TMC125 trial and were treated for at least 48 weeks. - N/A
Tibotec Pharmaceuticals Limited0 sites300 target enrollmentStarted: November 10, 2005Last updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Active, not recruiting
- Sponsor
- Enrollment
- 300
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •Subjects who meet all of the following criteria are eligible for this trial:
- •1. subject voluntarily signed the informed consent ;
- •2. subject was previously randomized to a TMC125 treatment arm:
- •a. in a partially blinded Phase II TMC125 trial, being treated with TMC125 and completed at least 48 weeks of treatment with TMC125; or
- •b. in a fully blinded Phase II TMC125 trial, being unblinded after being treated at least 48 weeks and identified as having received treatment with TMC125;
- •3. subject can comply with the protocol requirements;
- •4. subject's general medical condition, in the investigator's opinion, does not interfere with the assessments and the completion of the trial.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
Exclusion Criteria
- •Subjects meeting one or more of the following criteria cannot be selected:
- •1. use of disallowed concomitant therapy unless prior exemption has been granted;
- •2. any treatment-emergent condition or exacerbation of underlying condition during original Phase II trial, which in the investigator's opinion would likely compromise the subject's safety or compliance with the study procedures;
- •3. female or childbearing potential without the use of effective birth control methods or not willing to continue practicing these birth control methods during the trial and for at least 14 days after the end of the trial (or after the last intake of ART);
- •Note : Hormone-based contraception may not be reliable when taking TMC125, therefore to be eligible for this study woman of childbearing potential should either:
- •(1) use a double barrier method to prevent pregnancy (i.e., using a condom with either spermicidal cream/foam/gel or diaphragm or cervical cap; or
- •(2) use hormone-based contraceptives in combination with a barrier contraceptive (i.e., male condom, diaphragm or cervical cap with spermicide or female condom with spermicide); or
- •(3) use an intrauterine device (IUD) in combination with a barrier contraceptive (i.e., male condom, diaphragm or cervical cap with spermicide or female condom with spermicide); or
- •(4) be non-heterosexually active, practice sexual abstinence or have a vasectomized partner.
- •Note: Women who are postmenopausal for at least 2 years, women with total hysterectomy and women who have a tubal ligation are considered of non-childbearing potential.
- •4. A grade 3 elevation of amylase and/or lipase except for isolated grade 3 increases of amylase with lipase in normal range and no history of pancreatitis;
- •5. Any grade 4 toxicity according to the Division of AIDS (DAIDS) grading table; with the exception of grade 4 elevations of triglycerides or glucose asymptomatic or under non-fasting conditions; grade 4 elevation of glucose in subjects with pre-existing diabetes.
- •6. Subjects with clinical or laboratory evidence of significantly decreased hepatic function or decompensation, irrespective of liver enzyme levels (International Normalized Ratio [INR] > 1.5 or albumin < 30 g/l or bilirubin > 2.5 x ULN).
Investigators
Similar Trials
Active, not recruiting
Not Applicable
An open-label trial with TMC125 in HIV-1 infected subjects, who were randomized to a TMC125 treatment arm in a sponsor-selected TMC125 trial and were treated for at least 48 weeks. - N/AHIV-1 InfectionMedDRA version: 9.1Level: LLTClassification code 10020192Term: HIV-1EUCTR2005-000712-27-DETibotec Pharmaceuticals Limited300
Active, not recruiting
Not Applicable
An open-label trial with TMC125 in HIV-1 infected subjects, who were randomized to a TMC125 treatment arm in a sponsor-selected TMC125 trial and were treated for at least 48 weeks.EUCTR2005-000712-27-ITTIBOTEC PHARMACEUTICALS LTD.
Active, not recruiting
Phase 1
An open-label trial with TMC125 in HIV-1 infected subjects, who were randomized to a TMC125 treatment arm in a sponsor-selected TMC125 trial and were treated for at least 48 weeks. - N/AHIV-1 InfectionMedDRA version: 9.1 Level: LLT Classification code 10020192 Term: HIV-1EUCTR2005-000712-27-GBTibotec Pharmaceuticals Limited300
Active, not recruiting
Phase 1
An open-label trial with TMC125 in HIV-1 infected subjects, who were randomized to a TMC125 treatment arm in a sponsor-selected TMC125 trial and were treated for at least 48 weeks.EUCTR2005-000712-27-ESTibotec Pharmaceuticals Limited300
Active, not recruiting
Not Applicable
An open-label trial of TMC125 in HIV-1 infected subjects who were randomized to an active control arm of any sponsor-selected TMC125 trial and either virologically failed or completed the entire treatment period. - N/AHIV-1 infectionEUCTR2004-001658-10-ESTibotec Pharmaceuticals Limited60